Jun Takizawa
Overview
Explore the profile of Jun Takizawa including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
76
Citations
705
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Shimasaki Y, Miyoshi H, Kawamoto K, Yoshida N, Mishina T, Nakashima K, et al.
Cancer Med
. 2024 Jan;
13(3):e6793.
PMID: 38234210
Aim: Peripheral T-cell lymphoma not otherwise specified (PTCL-NOS) is a heterogeneous disease that can be classified into the PTCL-TBX21 and PTCL-GATA3 subtypes. Methods: In this study, we compared the clinicopathological...
12.
Takahashi H, Natsumeda M, On J, Watanabe J, Tada M, Shimizu H, et al.
Leuk Lymphoma
. 2023 Apr;
64(6):1219-1222.
PMID: 37070573
No abstract available.
13.
14.
Kawakami A, Kuroda H, Suzuki T, Kobayashi H, Abe S, Ui M, et al.
Rinsho Ketsueki
. 2022 Aug;
63(7):759-763.
PMID: 35922944
A 68-year-old male patient with lung adenocarcinoma, who was treated with chemotherapy and immune checkpoint inhibitors (ICIs), developed lymphadenopathy during treatment. His para-aortic lymph nodes increased to 2.0 cm in...
15.
Uemura S, Yamashita M, Aoyama K, Yokomizo-Nakano T, Oshima M, Nishio M, et al.
Biochem Biophys Res Commun
. 2022 Jun;
619:117-123.
PMID: 35753219
Radiation therapy is one of the major treatment modalities for patients with cancers. However, ionizing radiation (IR) damages not only cancer cells but also the surrounding vascular endothelial cells (ECs)....
16.
Miyazaki K, Suzuki R, Oguchi M, Taguchi S, Amaki J, Maeda T, et al.
Hematol Oncol
. 2022 Feb;
40(4):667-677.
PMID: 35142384
To elucidate the long-term outcomes of non-anthracycline-containing therapies and central nervous system (CNS) events in patients with extranodal NK/T-cell lymphoma, nasal type (ENKTL), the clinical data of 313 patients with...
17.
Izutsu K, Suzumiya J, Takizawa J, Fukase K, Nakamura M, Jinushi M, et al.
J Clin Exp Hematop
. 2021 Jun;
61(3):135-144.
PMID: 34092722
Mantle cell lymphoma (MCL) accounts for approximately 3% of all cases of malignant lymphoma in Japan. The CLIMBER-DBR (Treatment practices and patient burden in chronic lymphocytic leukemia and mantle cell...
18.
Takizawa J, Izutsu K, Nagai H, Fukase K, Nakamura M, Jinushi M, et al.
J Clin Exp Hematop
. 2021 Jun;
61(3):126-134.
PMID: 34092721
There are limited real-world data on the treatment practices and healthcare resource utilization associated with chronic lymphocytic leukemia (CLL) in Japan. In this study (CLIMBER-DBR), we performed retrospective analyses of...
19.
Terui Y, Rai S, Izutsu K, Yamaguchi M, Takizawa J, Kuroda J, et al.
Cancer Sci
. 2021 May;
112(7):2845-2854.
PMID: 33942442
Polatuzumab vedotin (pola) is a CD79b-targeted antibody-drug conjugate delivering a potent antimitotic agent (monomethyl auristatin E) to B cells. This was an open-label, single-arm study of pola 1.8 mg/kg, bendamustine...
20.
Mitobe M, Kawamoto K, Suzuki T, Suwabe T, Shibasaki Y, Masuko M, et al.
J Clin Exp Hematop
. 2021 Feb;
61(1):42-47.
PMID: 33551436
High-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements, also known as double-hit lymphoma, has been reported as refractory to R-CHOP therapy and requires more intensive regimens. However, intensive...